Coinfection
ICAAC 2012: Raltegravir Shows Long-term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
The HIV integrase inhibitor raltegravir (Isentress) was well-tolerated and demonstrated continued effectiveness for 5 years in treatment-naive and 3 years in treatment-experienced HIV patients coinfected with hepatitis B or C, according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.
ICAAC 2012: Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HBV Epidemiology & Mortality
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people who substituted tenofovir DF (Viread) for zidovudine (AZT; Retrovir) or abacavir (Ziagen) in their antiretroviral regimen saw a reduction in hepatitis B viral load, despite HBV resistance to lamivudine (3TC; Epivir), according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.
CROI: Long-term Tenofovir Promotes HBsAg Decline in HIV/HBV Coinfected People
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 20 March 2012 00:00
- Written by Liz Highleyman
Hepatitis B surface antigen (HBsAg) levels declined steadily in HIV/HBV coinfected patients treated with tenofovir for up to 8 years, especially those with rising CD4 T-cell counts, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.
AIDS 2012: HIV/HBV Coinfection Linked to Higher Mortality, More ART Liver Toxicity
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 21 August 2012 00:00
- Written by Liz Highleyman
Approximately 6% of people with HIV receiving antiretroviral treatment in Tanzania were coinfected with hepatitis B virus (HBV), which was associated with an elevated risk of death, smaller CD4 T-cell gains, and greater likelihood of liver toxicity, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.
HIV/HBV Coinfection Raises Risk of AIDS Progression and Death
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 13 December 2011 00:00
- Written by Liz Highleyman
Coinfection with hepatitis B virus (HBV) nearly doubled the risk of progression to AIDS or death among people recently infected with HIV, according to a study described in the December 5, 2011, advance online edition of the Journal of Infectious Diseases.
Hepatitis B Linked to More HIV+ Deaths than Hepatitis C, Risk High for People with AIDS
- Details
- Category: HIV/HBV Coinfection
- Published on Friday, 15 June 2012 00:00
- Written by Liz Highleyman
HIV positive men who are coinfected with hepatitis B virus (HBV) are more likely to die than those with hepatitis C virus (HCV) coinfection, according to research published in the April 20, 2012, advance online edition of Clinical Infectious Diseases. A related study, however, found that liver-related mortality was quite high for HIV/HCV coinfected people with a diagnosis of AIDS.
CDC Offers New HIV and Hepatitis Coinfection Fact Sheet
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 29 November 2011 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) have produced a new fact sheet providing information about viral hepatitis in people with HIV.
CROI: Detectable HIV Raises Risk of Incomplete Hepatitis B Suppression
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 27 March 2012 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people with detectable HIV viral load and higher baseline HBV viral load were less likely to completely suppress hepatitis B after a year on tenofovir (Viread), but CD4 cell count did not show an effect, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.
AASLD: Long-term Tenofovir for HIV/HBV Coinfection
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Tenofovir showed long-term antiviral activity against hepatitis B virus (HBV) lasting 5 to 8 years, with minimal evidence of kidney toxicity, and HBsAg levels declined steadily over time, according to 2 posters presented this week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
Web Design and Development by